Delft, Netherlands – September 15, 2026 -- AdJane Biosciences has published a technical white paper detailing a strategy to add a proprietary mucosal-immunity booster to established intramuscular respiratory vaccine franchises, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.
The paper, titled 'Boosting mRNA: Mucosal Immunity and a Platform Beyond It,' outlines a heterologous prime-boost regimen: existing intramuscular vaccines would prime systemic immunity, while an intranasal Nm-nOMV dose would generate complementary IgA responses at the respiratory mucosa, the initial entry point for pathogens.
Phase I data show intranasal Nm-nOMV induced significant nasal IgA in mRNA-primed subjects
In a post-hoc subgroup of AdJane's completed Phase I trial, participants previously immunized with Pfizer and/or Moderna mRNA COVID-19 vaccines received a subsequent intranasal dose of an Nm-nOMV vaccine expressing the SARS-CoV-2 spike protein. The booster was well tolerated and induced significant nasal IgA responses, providing early human evidence for the heterologous systemic-prime, mucosal-boost concept. AdJane said further clinical studies are needed to determine the magnitude, durability and clinical relevance of the additional mucosal response.
AdJane targets COVID-19, flu, RSV and combination respiratory vaccines for future application
While the initial clinical observations involve mRNA COVID-19 vaccine recipients, AdJane said limited mucosal immunity is a feature common to many intramuscular respiratory vaccination strategies, not just mRNA platforms. Pending further development and clinical validation, potential applications span COVID-19, influenza, RSV, combination respiratory vaccines and pandemic preparedness programs.
Company builds IP portfolio spanning platform, manufacturing and mRNA-OMV combinations
AdJane has developed a broad intellectual property portfolio covering the Nm-nOMV platform, manufacturing processes, mucosal delivery and vaccine-specific applications. The company has also filed separate patent applications covering combinations of OMV technology with mRNA vaccines and respiratory vaccines.
"Innovation in respiratory vaccines can build on what already works: vaccines that protect millions of people,